Expression of the human coagulation factor IX in the bone marrow mesenchymal stem cells

Background: Mesenchymal stem cells (MSCs) are appropriate target for gene and cell-based therapy of hemophilia B patients. MSCs possess several unique properties such as capability of differentiating into multiple lineages and lower immunogenecity in transplant procedure that make them attractive ca...

Full description

Bibliographic Details
Main Authors: Azadehsadat Azadbakhsh, Mohammad Reza Sam, Farah Farrokhi, Alireza Zomorodipour, Ali Akbar Haddad Mashahrizeh, Aram Mokarizadeh
Format: Article
Language:English
Published: Bushehr University of Medical Sciences 2014-05-01
Series:Iranian South Medical Journal
Subjects:
Online Access:http://ismj.bpums.ac.ir/browse.php?a_code=A-10-3-436&slc_lang=en&sid=1
id doaj-7d3ce5ee6439444c9ab3313600b0f2cb
record_format Article
spelling doaj-7d3ce5ee6439444c9ab3313600b0f2cb2020-11-24T21:03:50ZengBushehr University of Medical SciencesIranian South Medical Journal 1735-43741735-69542014-05-01172130140Expression of the human coagulation factor IX in the bone marrow mesenchymal stem cellsAzadehsadat Azadbakhsh0Mohammad Reza Sam1Farah Farrokhi2Alireza Zomorodipour3Ali Akbar Haddad Mashahrizeh4Aram Mokarizadeh5 Department of Cellular and Molecular Biotechnology, Institute of Biotechnology, Urmia University, Urmia, IRAN Department of Cellular and Molecular Biotechnology, Institute of Biotechnology, Urmia University, Urmia, IRAN Background: Mesenchymal stem cells (MSCs) are appropriate target for gene and cell-based therapy of hemophilia B patients. MSCs possess several unique properties such as capability of differentiating into multiple lineages and lower immunogenecity in transplant procedure that make them attractive candidates for cell and gene therapy. One of the challenges in the gene therapy is the low expression level of transgene. To improve expression, strong regulatory elements in the context of vectors could contribute to improve efficacy of gene therapy strategies. In this study four human factor IX (hFIX)-expressing plasmids equipped with various combination of human -globin (hBG) introns and Kozak sequence were transfected into the MSCs and expression of the hFIX was evaluated in vitro. Material and Methods: MSCs were obtained from tibias and the femora of rats and phenotypic characterization of the MSCs was determined by flow cytometry. Four hFIX-expressing plasmids were introduced into the culture-expanded MSCs using transfection agent. 48 hours after transfection, ability of the MSCs for expression of the hFIX and efficacies of the plasmids were evaluated by performing sandwich ELISA on cultured media as well as semi-quantitative RT-PCR. All analyses were performed with One-way ANOVA using SPSS software. Results:The highest expression level of the hFIX was obtained from intron-less and hBG intron-I containing construct. The highest biological activity was obtained from hBG intron-I,II containing construct. Conclusion:Successful expression of the hFIX was obtained from recombinant MSCs. MSCs were able to splice heterologous hBG intron-I from the hFIX-cDNA. Application of thehBG introns reduced the hFIX expression levels, probably due to improper splicing of the hBG introns.http://ismj.bpums.ac.ir/browse.php?a_code=A-10-3-436&slc_lang=en&sid=1mesenchymal stem cells hemophilia B human factor IX plasmid human β-globin introns
collection DOAJ
language English
format Article
sources DOAJ
author Azadehsadat Azadbakhsh
Mohammad Reza Sam
Farah Farrokhi
Alireza Zomorodipour
Ali Akbar Haddad Mashahrizeh
Aram Mokarizadeh
spellingShingle Azadehsadat Azadbakhsh
Mohammad Reza Sam
Farah Farrokhi
Alireza Zomorodipour
Ali Akbar Haddad Mashahrizeh
Aram Mokarizadeh
Expression of the human coagulation factor IX in the bone marrow mesenchymal stem cells
Iranian South Medical Journal
mesenchymal stem cells
hemophilia B
human factor IX
plasmid
human β-globin introns
author_facet Azadehsadat Azadbakhsh
Mohammad Reza Sam
Farah Farrokhi
Alireza Zomorodipour
Ali Akbar Haddad Mashahrizeh
Aram Mokarizadeh
author_sort Azadehsadat Azadbakhsh
title Expression of the human coagulation factor IX in the bone marrow mesenchymal stem cells
title_short Expression of the human coagulation factor IX in the bone marrow mesenchymal stem cells
title_full Expression of the human coagulation factor IX in the bone marrow mesenchymal stem cells
title_fullStr Expression of the human coagulation factor IX in the bone marrow mesenchymal stem cells
title_full_unstemmed Expression of the human coagulation factor IX in the bone marrow mesenchymal stem cells
title_sort expression of the human coagulation factor ix in the bone marrow mesenchymal stem cells
publisher Bushehr University of Medical Sciences
series Iranian South Medical Journal
issn 1735-4374
1735-6954
publishDate 2014-05-01
description Background: Mesenchymal stem cells (MSCs) are appropriate target for gene and cell-based therapy of hemophilia B patients. MSCs possess several unique properties such as capability of differentiating into multiple lineages and lower immunogenecity in transplant procedure that make them attractive candidates for cell and gene therapy. One of the challenges in the gene therapy is the low expression level of transgene. To improve expression, strong regulatory elements in the context of vectors could contribute to improve efficacy of gene therapy strategies. In this study four human factor IX (hFIX)-expressing plasmids equipped with various combination of human -globin (hBG) introns and Kozak sequence were transfected into the MSCs and expression of the hFIX was evaluated in vitro. Material and Methods: MSCs were obtained from tibias and the femora of rats and phenotypic characterization of the MSCs was determined by flow cytometry. Four hFIX-expressing plasmids were introduced into the culture-expanded MSCs using transfection agent. 48 hours after transfection, ability of the MSCs for expression of the hFIX and efficacies of the plasmids were evaluated by performing sandwich ELISA on cultured media as well as semi-quantitative RT-PCR. All analyses were performed with One-way ANOVA using SPSS software. Results:The highest expression level of the hFIX was obtained from intron-less and hBG intron-I containing construct. The highest biological activity was obtained from hBG intron-I,II containing construct. Conclusion:Successful expression of the hFIX was obtained from recombinant MSCs. MSCs were able to splice heterologous hBG intron-I from the hFIX-cDNA. Application of thehBG introns reduced the hFIX expression levels, probably due to improper splicing of the hBG introns.
topic mesenchymal stem cells
hemophilia B
human factor IX
plasmid
human β-globin introns
url http://ismj.bpums.ac.ir/browse.php?a_code=A-10-3-436&slc_lang=en&sid=1
work_keys_str_mv AT azadehsadatazadbakhsh expressionofthehumancoagulationfactorixinthebonemarrowmesenchymalstemcells
AT mohammadrezasam expressionofthehumancoagulationfactorixinthebonemarrowmesenchymalstemcells
AT farahfarrokhi expressionofthehumancoagulationfactorixinthebonemarrowmesenchymalstemcells
AT alirezazomorodipour expressionofthehumancoagulationfactorixinthebonemarrowmesenchymalstemcells
AT aliakbarhaddadmashahrizeh expressionofthehumancoagulationfactorixinthebonemarrowmesenchymalstemcells
AT arammokarizadeh expressionofthehumancoagulationfactorixinthebonemarrowmesenchymalstemcells
_version_ 1716772788643037184